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ness of azithromycin 500mg/day QD and clarithromycin 1g/day BID for the treat-
ment of CAP for immunocompetent individuals age 65 and older from the private
healthcare perspective in Brazil.METHODS: A decision-tree model, built based on
the following health states: death, cure and discontinuing due to adverse events
(phlebitis, diarrhea, infusion reaction which would lead to switching the antibiot-
ics). Risks and length of treatment were obtained from the literature and prices
were retrieved from the Brazilian Hierarchic Classification of Medical Procedures
(CBHPM 4th edition - 2005) and public databases. Resource Utilization (exams,
procedures andmaterials) were gathered based on the latest clinical guidelines for
CAP defined by the Brazilian Society of Pneumology. The time horizon was defined
as one year. Effectiveness was expressed as life years gained (LYG). Values were
expressed in 2011 USD. First order probabilistic sensitivity analysis was carried by
Monte Carlo simulation of 10,000 iterations considering the range of values for the
lengths of treatment in a normal distribution. RESULTS: The simulation consider-
ing 10,000 iterations showed the following values for azithromycin and clarithro-
mycin respectively: Total LYG [9,640 vs. 8,840]; average costs per treatment
[USD863.76 vs. USD1,384.15]; average cost-effectiveness ratio [USD896.04/LYG vs.
USD1,566.18/LYG], representing a cost saving of USD 670.14/LYG for azithromycin.
Considering 100,000 cases of pneumonia hospitalizations for adults age 65, the total
savings for the incorporationofazithromycinwouldbeapproximatelyUSD52.072.571.
CONCLUSIONS: In this analysis, azithromycin presented the greatest effectiveness
diminishing costs, by reducing mortality and treatment discontinuation due to
adverse events, from the Brazilian private health care system’s perspective.
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OBJECTIVES: According to Brazilian public databases (DATASUS), community ac-
quired pneumonia (CAP) requiring hospitalization for individuals of age 65 have a
mortality relative risk increase of 4.05 when compared to the average rate of
younger ages. This study has the objective of evaluating the cost-effectiveness of
azithromycin 500mg/day QD and clarithromycin 1g/day BID for the treatment of
CAP for immunocompetent individuals age 65 and older from the public healthcare
perspective in Brazil.METHODS: A decision-tree model, built based on the follow-
ing health states: death, cure and discontinuing due to adverse events (phlebitis,
diarrhea, infusion reaction which would lead to switching the antibiotics). Risks
and length of treatment were obtained from the published literature and acquisi-
tion costs were retrieved from Brazilian public databases (Banco de Preços em
Saúde and SIGTAP - Sistema de Gerenciamento da Tabela de Procedimentos, Me-
dicamentos e OPMdo SUS). Resource utilization (exams, procedures andmaterials)
were gathered based on the latest clinical guidelines for CAP defined by the Brazil-
ian Society of Pneumology. The timehorizonwas defined as one year. Effectiveness
was expressed as life years gained (LYG). Values were expressed in 2011 USD. First
order probabilistic sensitivity analysis was carried by Monte Carlo simulation of
10,000 iterations considering the range of values for the lengths of treatment in a
normal distribution. RESULTS: Simulation considering 10,000 iterations showed
the following values for azithromycin and clarithromycin respectively: Total LYG
[9,640vs.8,840]; average costs per treatment [USD614.11vs.USD618.15]; average
cost-effectiveness ratio [USD637.07/LYGvs.USD699.23/LYG], representing a cost
saving per patient of USD62.17/LYG for azithromycin. Considering 180,851 cases of
pneumonia hospitalizations for adults age 65 registered at public hospitals in
Brazil(2010), the overall estimated savings for the incorporation of azithromycin
would be approximately USD730,561.15. CONCLUSIONS: In this analysis, azithro-
mycin presented the greatest effectiveness diminishing costs, by reducing mortal-
ity and treatment discontinuation due to adverse events.
PRS16
ECONOMIC BURDEN ASSOCIATED WITH ACUTE EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN CHINA
Yang HY1, Wu J2, Zheng Y2, Xie K2, Jin L3, Xie J4, Wu EQ5
1Tulane University, New Orleans, LA, USA, 2Tianjin University, Tianjin, China, 3Bureau of
Human Resource and Social Security, Tianjin, China, 4Analysis Group, Inc., New York, NY, USA,
5Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: To estimate the economic burden associated with acute exacerba-
tions of chronic obstructive pulmonary disease (COPD) in Tianjin, China.
METHODS: Data from the Tianjin Urban Employee Basic Medical Insurance
(UEBMI) database (2003-2007), including inpatient claims for medical services and
prescription drugs from 30% random sample of enrollees, were used. Acute exac-
erbationwas defined as aCOPDepisode leading to hospitalization. Hospitalizations
of adult patientswith primary diagnosis of COPDanddischarge dates between 2003
and 2007 were selected and the latest COPD hospitalization for each patient was
selected to estimate healthcare utilization and costs associated with COPD acute
exacerbation. All costs were estimated in 2007 U.S. dollars using the Medical Ser-
vice Consumer Price Index (CPI) in China and an exchange rate of 7.598 Chinese
Yuan to 1 USD in 2007. RESULTS: A total of 1321 COPD patients with acute exacer-
bations were identified, with a mean age of 71.1 years and 41.3% female. Approxi-
mately 38.4% of all patients had at least one complication, 21.3% had cor pulmo-
nale, 19.8% had pneumonia, 11.0% had congestive heart failure, and 4.9% had
bronchiectasis. About 58.2% hospitalizations occurred in tier-3 hospitals, 36.2% in
tier-2 hospitals and 5.6% in tier-1 hospitals. The mean length of stay was 16.8 days
per hospitalization. About 92.9% patients received antiathmatic, 75.2% received
expectorant, and 24.6% received antitussive during hospitalization. Themean total
cost per acute exacerbation/hospitalization was $1323 with 74.1% covered by
UEBMI and 25.9% by patients. Medication costs accounted for 56.3% of the total
inpatient costs. Examination costs and bed costs accounted for 16.4% and 4.5%,
respectively. CONCLUSIONS: Complications of COPD are common among patients
with COPD exacerbations. The majority of patients with COPD exacerbations are
treated in tier-3 hospitals. COPD exacerbations incur high health care utilization
and costs. Medication costs account for the majority of the costs associated with
exacerbations.
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OBJECTIVES: To estimate the national prevalence and the direct incremental costs
of Chronic Obstructive Pulmonary Disease (COPD) and asthma using the 2007Med-
ical Expenditure Panel Survey (MEPS) data. METHODS: This was a retrospective
study of patient records identified using ICD-9-CM diagnosis and procedure codes
for principal diagnosis of COPD (491.0, 492.0, 496.0) and asthma (493.0, 493.1, 493.2)
from the 2007 MEPS data. The main independent variable was the presence or
absence of either COPD or asthma. Age, gender, race, income, insurance status,
marital status and region were selected as covariates. The dependent variables
were total health care, office-based, outpatient, inpatient, emergency room, and
prescription expenditures. Descriptive statistics and regression analyses were uti-
lized to generate prevalence data, total mean health care expenditures, and signif-
icant predictors for individuals with COPD and asthma. RESULTS: The national
prevalence of COPD and asthma in 2007 was estimated at 1.3 million and 28.3
million, respectively. Among individuals with COPD, the estimated total direct
incremental health care expenditures per person was $1739.27 with a national
estimate of $2.2 billion. Among individuals with asthma, the estimated total direct
incremental health care expenditure per person was $2133.83 with a national es-
timate of $60 billion. The largest cost category for COPD was office-based expendi-
tures ($610.55) followed by prescription expenditures ($347.88). For asthma, the
largest cost categories were prescription expenditures ($760.72) followed by inpa-
tient expenditures ($617.23). Age, gender, region, insurance and marital status
were significant predictors for health care expenditures in COPD and asthma.
CONCLUSIONS: This study highlights the socio-demographic disparities in terms
of prevalence and provides national estimates on health care expenditures among
individuals with COPD and asthma. These estimates can serve as a guide for policy
makers in the formulation of health care policies on screening, treatment guide-
lines, and identification of high-risk population for COPD and asthma.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading
cause of death in the world and remains a disease with substantial residual mor-
bidity and cost burden. Current evidence-based guidelines focus attention on
achieving and maintaining disease stability and reducing the incidence of exacer-
bations as important management targets. Few disease-based models exist for
COPD. Our objective was to develop a dynamic, natural history model that reflects
progression of COPD, events and treatments that characterize its management.
METHODS:We developed an Excel-based Markov model with 4 health states rep-
resenting the Global Burden of Lung Disease (GOLD) disease severity classification.
Within each GOLD stage, we model stable disease with three levels of COPD exac-
erbation. We include 2 health states for end-stage treatments (lung transplant and
lung volume reduction surgery [LVRS]) as well as death. Data to populate progres-
sion comes from published clinical studies and lung function data collected within
the Framingham Heart Study. The model simulates disease progression, severity
and event- and stage specific mortality, exacerbations and quality-adjusted sur-
vival over a lifetime. Cost parameters reflect 2010 US resource use. RESULTS: We
calibratedmodel progression andmortality using data from the 5-year LungHealth
Study. Initiating a cohort simulationwith a 60 year old, 79.2% of the cohort remains
in GOLD stage I and II after 5 years. The simulation produces average annual costs
of $970, $5,700, $13,000, and $13,700for GOLD stages I to IV, respectively. Only a
small fraction (2%) of the cohort progresses to transplant and LVRS. Over 91% of
the cohort survived through the 5-year simulation, with a background mortality
rate for 60-year-olds at almost 1% annually. CONCLUSIONS: A natural history
model of COPD can be useful for estimating disease progression, costs and the
impact of new technologies. Future research is needed to validate the model pre-
dictions.
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OBJECTIVES: To estimate COPD exacerbation incidence rates, related costs, and
predictors among managed care patients treated for chronic bronchitis (CB).
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